Race Oncology

Through October, the National Breast Cancer Foundation (NBCF) has been raising awareness about the importance of being breast aware. Early detection and better treatments are key in the fight against breast cancer, affecting over 21,000 women and men in Australia every year.    At Race Oncology, we're advancing research with RC220, a drug aiming to improve breast and other cancer treatment while protecting patients from the serious side effects of cancer treatment. We support NBCF’s goal of Zero Deaths through developing life-saving research and novel oncology treatments.   Learn more at nbcf.org.au   #BreastCancerAwarenessMonth #PinkRibbon #ZeroBy2030 #RaceOncology

Race Oncology CEO and Managing Director Dr Daniel Tillett spoke with ausbiz about the milestones achieved in the first quarter of FY2025.    Dr Tillett highlighted that Race is currently well-funded into 2028, while current clinical and pre-clinical programs are advancing smoothly. In particular, Race is soon to commence a cardioprotective clinical program that will see the new formulation of Race’s lead drug asset, RC220 bisantrene, being used in combination with other chemotherapeutic drugs to improve treatment and patient outcome.    Dr Tillett also spoke about a $20 million R&D Tax Incentive that Race has been granted, and will be used to support the company’s eligible overseas activities.    Watch the full interview here: https://lnkd.in/gs85CHiQ   #cardioprotection #bisantrene #oncologydrugs

Race Oncology is pleased to release our Quarterly Activity Report for the period ending 30 September 2024 (Q1 FY 2025).   This productive quarter saw the conclusion of the Phase 1b/2 trial of bisantrene in acute myeloid leukaemia (AML) patients, key board renewal changes including the appointment of Dr Peter Smith as Executive Chair, progress of the RC220 bisantrene Phase 1a/b human trial, and a positive outcome of an R&D Tax Incentive Advance and Overseas Finding Assessment.    Race CEO and Managing Director, Dr Daniel Tillett commented: "I wish to warmly welcome Serge and Prof Von Hoff to Race. The Race team has continued to work diligently as we advance RC220 bisantrene to the clinic as a potential novel cardioprotective anticancer treatment for use with anthracycline chemotherapeutics. I would also like to thank the Australian Government for their recognition of the importance of Race’s R&D activities via the $20m overseas advance ruling.”   For further details on the key milestones from the period and to interact with Race’s management team, please head to Race’s Investor Hub: https://lnkd.in/gCgxPnKK   #cardioprotection #bisantrene #oncology

Race Oncology is pleased to share that in his latest research report, MST Financial Senior Life Science Analyst Chris Kallos, CFA increased his #RAC valuation to A$6.37 per share.    This increase in valuations is based on three key considerations: - Race’s lead drug asset #bisantrene enables greater dosing of anthracyclines  - Reformulated bisantrene RC220 is on schedule to enter human clinical trials in CY24  - Fully funded for current programs   The report notes: “We have revised our valuation to reflect a potential role for bisantrene in optimising the use of anthracyclines and its subsequent use in combination across all cancer indications. This scenario recognises both bisantrene's cardioprotective qualities and its anti-cancer potential and assumes its use in all anthracycline regimens… As such, we value Race Oncology at A$6.37 per share (versus A$3.22 previously) and A$5.30 per share on a fully diluted basis.”   To read the full report, and interact with Race’s management team, visit our Investor Hub via this link: https://lnkd.in/g8Yiw_fE   #BiotechInvestment #cardioprotection #OncologyTreatment

Race Oncology Executive Chair Dr Peter Smith spoke with Stockhead about the company’s lead drug asset #bisantrene and its unique #cardioprotective properties, post his presentation at #HealthInvest 2024 Conference, hosted by IR Department and Morgans Financial Limited.    Watch a full interview with Dr Smith via the thumbnail below. To read the news story on HealthInvest 2024 and interact with Race’s management team, head to our Investor Hub via this link: https://lnkd.in/gGGCMK-e #BiotechInvestment #Oncology #DrugDevelopment

Race Oncology has been invited to present at the E&P Annual Small Cap Healthcare Event this Thursday 26 September in Sydney. We look forward to presenting an update on the development progress of our lead #oncology drug, RC220 bisantrene, and the latest clinical plans.   Thank you E&P Financial Group for the opportunity to join other life science companies, along with institutional and sophisticated investors, to discuss the latest innovations in the #biotech sector.   #smallcapinvesting #cardioprotection $RAC

#HealthInvest’s SYD event is coming up on 18 Sep. Meet our featured presenter of the day, Dr. Peter Smith, Executive Chair at Race Oncology (ASX: RAC), who has over 35 years of experience in the pharmaceutical and biotech industry, with a focus on oncology. Pete was previously CEO of Myrio Therapeutics and co-founded Onyvax Ltd, with a PhD from the University of Cambridge. Want to learn more and watch Pete’s presentation? Click here to register: https://lnkd.in/gA4_EepK #lifesciences #RaceOncology

Race Executive Chair Dr Peter Smith speaks with Proactive about the board changes announced recently, welcoming Dr Serge Scrofani to the Race board as the new Non-Executive Director.   In this interview, Dr Smith elaborates on Race’s lead drug asset #bisantrene’s cardioprotective properties, and the difference the drug can make to patients’ quality of life post cancer treatment.   Watch the full interview below and on Race’s Investor Hub:  https://lnkd.in/ehgBDZep   #cardiotoxicity #oncologytreatment #biotech

This September, during Childhood Cancer Awareness Month, we’d like to acknowledge the children and families impacted by #cancer.   At Race Oncology, our hope is to see a world where every child has access to effective cancer treatments that limit the impact of side effects and offer a chance for a healthy future.   #ChildhoodCancerAwarenessMonth #bisantrene #cardioprotection #paediatriccancer

As part of Race Oncology’s Board Renewal process, we have announced a number of changes designed to support our clinical development pathway and commercialisation strategy. These changes include: - Non-Executive Chair, Ms Mary Harney and Non-Executive Director, Mr Phil Lynch to retire from the Board; - Dr Peter Smith appointed as Executive Chair and Dr Daniel Tillett appointed as Managing Director and Chief Executive Officer; - Dr Serge Scrofani joins Race as an Independent Non-Executive Director. The appointment of Dr Serge Scrofani to the Board is an exciting one for Race as he brings more than 28 years’ experience in the healthcare sector, working in global roles across research and strategy, and corporate and business development. Serge served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a pivotal role in multiple global strategic initiatives. Mary Harney, outgoing Non-Executive Chair commented, “Phil and I are grateful for the time we’ve had with Race through which time the Company’s shape and strategy has advanced considerably. With Race in a state of strength and stability, we have determined this is a good time for us to step aside, enabling the board and Company to continue to evolve. In parallel with the above changes, we are very pleased to welcome Dr Scrofani, who brings deep and diverse experience in global deal-making across M&A and licensing. We look forward to the contribution Serge will make to Race and believe an appointment of such calibre is testament to the organisation we have been building.”   For further details and to watch a video interview where Dr Pete Smith, Dr Daniel Tillett and Dr Serge Scrofani discuss the board renewal in further detail, please click the following link:  https://lnkd.in/gU5qbVwa